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Summary
Background and Objectives: Early life is a critical window for adiposity programming.
Metabolic-profile in early life may reflect this programming and correlate with later
life adiposity. We investigated if metabolic-profile at 3 months of age is predictive for
body composition at 2 years and if there are differences between boys and girls and
between infant feeding types.
Methods: In 318 healthy term-born infants, we determined body composition with
skinfold measurements and abdominal ultrasound at 3 months and 2 years of age.
High-throughput-metabolic-profiling was performed on 3-month-blood-samples.
Using random-forest-machine-learning-models, we studied if the metabolic-profile at
3 months can predict body composition outcomes at 2 years of age.
Results: Plasma metabolite-profile at 3 months was found to predict body composi-
tion at 2 years, based on truncal: peripheral-fat-skinfold-ratio (T:P-ratio), with a pre-
dictive value of 75.8%, sensitivity of 100% and specificity of 50%. Predictive value
was higher in boys (Q2 = 0.322) than girls (Q2 = 0.117). Of the 15 metabolite vari-
ables most strongly associated with T:P-ratio, 11 were also associated with visceral
fat at 2 years of age.
Abbreviations: BCAA, branched chain amino acids; BMI, body mass index; EBF, exclusive breast feeding; EFF, exclusive formula feeding; FDR, false discovery rate; GLM, generalized linear
models; HPLC, high performance liquid chromatography; LC–MS, liquid chromatography with mass spectrometry detection; LDL, low-density lipoprotein; LysoPA, lysophosphatidic acid; LysoPE,
lysophosphatidylethanolamine; LysoPG, lysophosphatidylglycerol; LysoPS, lysophosphatidylserine; m/z, mass-to-charge ratio; mTOR, mechanistic target of rapamycin; NCD, non-communicable
diseases; PC, phosphatidylcholine; PCA, principal component analysis; PLS-DA, partial least squares – discriminant analysis; PPAR-γ, peroxisome proliferator-activated receptor gamma; S:V-ratio,
subcutaneous:visceral fat ratio; SD, standard deviation; T:P-ratio, truncal:peripheral skinfold ratio; TLR, toll-like receptor; UV, unit variance; WHO, World Health Organization.
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Conclusion: Several plasma metabolites (LysoPC(22:2), dimethylarginine and others)
at 3 months associate with body composition outcome at 2 years. These results high-
light the importance of the first months of life for adiposity programming.
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1 | INTRODUCTION
Childhood obesity is an increasing and worldwide problem. In 1990,
32 million young children had overweight or obesity and this number
increased to 41 million in 2016.1 Obesity at young age does not only
cause short-term morbidity, but also increases the risk of developing
non-communicable diseases (NCD) in later life, such as insulin resis-
tance, type 2 diabetes and cardiovascular disease.1,2
The first months of life are a critical window for metabolic program-
ming affecting adult outcome and body composition.3,4 It has been
reported that a high weight-to-height SD score and a high BMI in child-
hood are predictive for overweight and obesity in adolescence and adult-
hood.5,6 It is also known however, that a similar body weight or BMI may
be accompanied by a different body composition or fat mass percentage,
especially in infants and young children.7,8 We have previously reported
that rapid weight gain in the first 6 months of life is an important risk fac-
tor for a higher fat mass in early adulthood3 and that infants with a rapid
rise in fat mass during the first 6 months of life have higher fat mass per-
centage trajectories during the first 2 years of life.9 Fat mass and its distri-
bution play an important role in the development of unfavourable
metabolic outcomes.10,11 Especially excessive truncal and visceral fat
accumulation compared to peripheral fat is associated with an
unfavourable metabolic profile.12 The ability to identify infants at risk of
obesity at an early stage, will provide the opportunity to develop more
targeted preventative strategies.
Also feeding type during the first few months of life influences body
composition, with infants receiving exclusive breastfeeding exhibiting dif-
ferent weight trajectories with more subcutaneous fat accumulation and
different serum concentrations of appetite regulating hormones com-
pared to infants receiving exclusive formula feeding.13,14
An unfavourable body composition with excessive body fat and
more visceral fat is associated with an adverse lipoprotein profile in
children and adults, especially with high LDL cholesterol levels, which
increases the risk of cardiovascular disease.15,16 However, not only
the standard lipoproteins, but also several hundred lipid species were
found in infant plasma.17 These could potentially be early biomarkers
for unfavourable metabolic outcomes.
Koulman et al. found that the metabolic and lipid profile of exclusively
breastfed infants is different from exclusively formula-fed infants. In
breastfed infants, total phosphatidylcholine levels are higher and linoleic
acid is less incorporated in palmitate into the phospholipid fraction as
compared to that of formula fed infants.18,19 In formula-fed infants, also
the amount of formula feeding did influence the metabolic profile. In addi-
tion, in infants aged 3 months, phosphatidylcholine (PC) (18:1/16:0) and
PC plasmalogen (34:1) were associated with accelerated weight gain,
while phosphatidylcholine (20:4/18:0), PC plasmalogen (36:4),
Sphingomyelin (d18:1/16:0) had an association with poor weight gain.18,20
These differences in metabolic profile and phospholipid composition
could change the endogenous lipid metabolism and, thus, have conse-
quences for adiposity programming and vice versa. We, therefore,
hypothesized that specific metabolites in early life associate with body
composition parameters at 2 years. The primary objective was to investi-
gate if metabolites at 3 months of age are associated with, and even may
predict specific body composition outcomes at age 2 years in a cohort of
healthy infants. Second, we aimed to investigate if any metabolites, pre-
dictive of 2 years body composition, already associated with body com-
position parameters at 3 months. Lastly, we investigated if the metabolite
profile at 3 months was different between boys and girls and between
infants with exclusive breastfeeding and those with exclusive formula
feeding.
2 | MATERIAL AND METHODS
2.1 | Subjects
The cohort consisted of infants participating in the Sophia Pluto study, an
ongoing birth cohort study of healthy infants, aimed to provide detailed
data on early growth- and body composition trajectories in infancy and
childhood. Infants were recruited between January 2013 and November
2017, from several maternity wards in Rotterdam, the second largest city
in the Netherlands. All participants met the following inclusion criteria:
born term (≥37 weeks of gestation), an uncomplicated neonatal period,
without severe asphyxia (defined as an Apgar-score below 3 after 5 min),
sepsis or the need for respiratory ventilation.
Exclusion criteria were maternal disease or medication that could
interfere with fetal growth, including maternal corticosteroids, insulin-
dependent (gestational) diabetes mellitus, known congenital or post-
natal disease or intrauterine infection that could interfere with infant
growth. The Medical Ethics Committee of Erasmus Medical Centre
approved the study. We obtained written informed consent of all par-
ents/caregivers with parental authority.
2.2 | Data collection and measurements
Trained staff carried out the measurements according to standard proce-
dures at 3 months and at 2 years. Birth data were taken from medical
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records. Parental characteristics and feeding type were obtained by stan-
dardized interviews at the clinic visits and by questionnaires. Details
about frequency and amount of infant feeding and dates of changes in
feeding mode were recorded. Exclusive breastfeeding (EBF) was defined
as receiving only mother's milk until at least the age of 3 months. Exclu-
sive formula feeding (EFF) was defined as receiving only infant formula
starting before the age of 1 month. Mixed feeding (mix) was defined as
starting with formula feeding between 1 and 3 months of age.
2.3 | Anthropometrics
Weight was measured to the nearest 5 g by an electronic infant scale
(Seca 717, Hamburg, Germany). Length was measured twice in supine
position to the nearest 0.1 cm by an infantometer (Seca 416). BMI was
calculated as weight (kg)/length2 (m2). Head, waist and hip circumference
were measured to the nearest 0.1 cm by a circumference measuring tape
(Seca 201). Skinfolds were measured to the nearest mm with a skinfold
calliper (Slimguide C-120, Creative Health) at every visit on four sites on
the left side of the body: biceps, triceps, subscapular and suprailliac. The
intra-observer intra class correlation coefficient (ICC) and inter-observer
ICC were determined earlier; 0.88 and 0.76, resp..21 Peripheral skinfolds
were calculated as triceps + biceps. Truncal skinfolds were calculated as
subscapular + suprailliac.21 The truncal:peripheral skinfold ratio (T:P-ratio)
was calculated as truncal skinfolds divided by peripheral skinfolds.
SD-scores of weight, length and weight-for-length were calculated
using Growth Analyser software (http://www.growthanalyser.org).22
2.4 | Abdominal fat
Abdominal visceral and subcutaneous fat were determined at 3 months
and 2 years, using ultrasound (Prosound 2 ultrasound with a UST-9137
convex transducer [both Hitachi Aloka Medical, Zug, Switzerland]). Fat
depths were measured in supine position, with the transducer on the
intercept of the xiphoid line and the waist circumference measurement
plane. Visceral fat was measured in the longitudinal plan from the perito-
neal boundary to the corpus of the lumbar vertebra with a probe depth
of 9 cm and abdominal subcutaneous fat in the transvers plan from the
cutaneous boundary to the linea alba with a probe depth of 4 cm. Mini-
mal pressure was applied. Validity and reproducibility of measurements
were confirmed in the Cambridge Baby Growth Study (CBGS), the rela-
tive interobserver technical error of measurement was 3.2% for visceral
fat and 3.6% for subcutaneous fat.23 If the vertebra were not visualized,
measurements were considered unsuccessful and were excluded from
analyses. The abdominal subcutaneous:visceral fat ratio (S:V-ratio) was
calculated as abdominal subcutaneous fat divided by visceral fat.
2.5 | Sample collection
Blood samples were collected at 3 months and 2 years by capillary
toe or finger prick sampling after the infants had fasted for a minimum
of 2 h. Blood was collected in heparin microtubes (BD Microtainer®,
200–400 μl) and centrifuged to prepare plasma. The samples were
stored at –80C until analysis. Plasma samples were transported on
dry ice to the University of Cambridge (UK) for metabolic profiling.
2.6 | Metabolic profiling
Metabolic profiling was performed with high throughput platform
in the Metabolic Research Laboratories of the Institute of Meta-
bolic Science in Cambridge. The samples were analysed using liq-
uid chromatography mass spectrometry method24 ultimately
yielding results of the absolute and relative concentration of
349 individual metabolites and lipids. The protein precipitation liq-
uid extraction protocol was used as described previously.24 Briefly,
50 μl of plasma was transferred into a 2 ml screw cap Eppendorf
plastic tube (Eppendorf, Stevenage, UK). Immediately, 650 μl of
chloroform was added to each sample, followed by thorough
mixing. Then, 100 μl of the internal standards (5 μM in methanol),
100 μl of the carnitine internal standards (5 μM in methanol) and
150 μl of methanol was added to each sample, followed by thor-
ough mixing, after which 400 μl of acetone was added to each
sample. The samples were vortexed and centrifuged for 10 min at
20 000 g to pellet any insoluble material. The supernatant was
pipetted into separate 2 ml screw cap amber-glass auto-sampler
vials (Agilent Technologies, Cheadle, UK). The organic extracts
were evaporated to dryness using a Concentrator Plus system
(Eppendorf, Stevenage, UK) run for 60 min at 60C. The samples
were reconstituted in 100 μl of a 2:1:1 mixture of propan-2-ol,
acetonitrile and water, and then thoroughly vortexed. The rec-
onstituted sample was transferred into a 250 μl low-volume vial
insert inside a 2 ml amber glass auto-sample vial ready for liquid
chromatography with mass spectrometry detection (LC–MS)
analysis.
Chromatographic separation was achieved using Shimadzu HPLC
System (Shimadzu UK Limited, Milton Keynes, UK) with the injection
of 10 μl onto a Waters Acquity UPLC® CSH C18 column (Waters,
Hertfordshire, UK); 1.7 μm, I.D. 2.1  50 mm2, maintained at 55C.
Mobile phase A was 6:4 acetonitrile and a 10 mM ammonium formate
solution in water. Mobile phase B was 9:1 propan-2-ol and a 10 mM
ammonium formate solution in acetonitrile. The flow was maintained
at 500 μl/min through the following gradient: 0.00 min_40% mobile
phase B; 0.40 min_43% mobile phase B; 0.45 min_50% mobile phase
B; 2.40 min_54% mobile phase B; 2.45 min_70% mobile phase
B; 7.00 min_99% mobile phase B; 8.00 min_99% mobile phase B;
8.3 min_40% mobile phase B; and 10 min_40% mobile phase B. The
sample injection needle was washed using 9:1, propan-2-ol and aceto-
nitrile. The mass spectrometer used was the Thermo Scientific
Exactive Orbitrap with a heated electrospray ionization source
(Thermo Fisher Scientific, Hemel Hempstead, UK). The mass spec-
trometer was calibrated immediately before sample analysis using
positive and negative ionization calibration solution (recommended by
instrument manufacturer). Additionally, the mass spectrometer scan
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rate was set at 4 Hz, giving a resolution of 25 000 (at 200 m/z) with a
full-scan range of m/z 100–1800 with continuous switching between
positive and negative mode.
2.7 | Data processing
All .RAW files were converted to .mzXML files using msConvert
(ProteoWizard).25 Converted files were subsequently processed in R
(v3.3.1) using the CAMERA package26 with peak picking performed
using the centWave method as this enables for the deconvolution of
closely eluting and slightly overlapping peaks. Metabolite variables
included within the final dataset were defined as peaks that had an
intensity at least three times higher in analytical samples relative to
the extraction blanks and that was present in at least 90% of the
analysed samples. If possible, metabolite variables were putatively
annotated by matching measured accurate masses to entities in the
Human Metabolome database (www.hmdb.ca).
2.8 | Statistical analysis
Clinical characteristics are expressed as mean and standard deviation
(SD) or as median and interquartile range (IQR) when not normally dis-
tributed. Differences in clinical characteristics were determined by
independent Student's t test or Mann–Whitney U-test for non-
parametric parameters. Pearson's correlation coefficient was used to
determine bivariate correlations. Exact power calculations for this
type of experiments were not readily available at the design of the
project. Previous analyses of the lipid profiles in the Cambridge Baby
Growth Study showed significant associations with catch-up growth18
using around 215 samples. By using the Sophia Pluto cohort, that is
almost double in sample size, sufficient power was considered to find
metabolites that are associated with fat distribution.
Using WHO classification, overweight was defined as a weight-
for-length > 2 SDS and obesity was defined as a weight-for-length > 3
SDS.1 Underweight was defined as an weight-for-age < 2 SDS.27
To analyse the association between metabolite profile and six
measures of body composition, peripheral and truncal fat, subcutane-
ous and visceral fat and the ratio of truncal:peripheral fat and the ratio
of abdominal subcutaneous:visceral fat, individuals were stratified into
tertiles of each body composition measure (‘high’, ‘middle’ and ‘low’).
Multivariate analysis was performed using principal component analy-
sis (PCA). Partial least squares – discriminant analyses (PLS-DA), per-
formed in SIMCA v13.0 (Umetrics, Umeå, Sweden), were used to
identify associations between the metabolite profiles generated from
samples collected at 3 months of age and body composition at 2 years
of age, with all data logarithmically transformed (base10) and scaled
to unit variance (UV) in all models. The performance of the generated
models was based on cumulative correlation coefficients R2X[cum]
and R2Y[cum] (PLS-DA only) to assess what percentage of the varia-
tion in the X and Y variables was explained by the model. The predic-
tive performance of these models was based on the 7-fold cross
validation Q2[cum] and the significance of the model was determined
using ANOVA of the cross validation residuals (CV-ANOVA).
To estimate if it is possible to determine body composition at
2 years of age using metabolite profile data from 3 months of age,
random forest machine learning models were performed in R (V3.3.1).
Each of the body compositions measures were split into a training
(70%) and testing set (30%). The performance of these models was
assessed by looking at overall classification accuracy of predicating
‘high’ or ‘low’ body composition measures, as well as the sensitivity
and specificity of the predictions made in the testing set. Univariate
analysis of metabolites of interest was performed using generalized
linear models (GLM) calculated in R (v3.3.1). We corrected for possible
confounders: sex, birth weight and feeding type. Additional correc-
tions for BMI SDS at age 3 months, weight-for-length SDS and total
skinfolds at age 2 years did not change the results. To determine dif-
ferences between boys and girls and between the different types of
feeding type, models were performed for boys and girls separately
and for EBF, EFF and mixed feeding separately.
Controlling for the false discovery rate (FDR) was done by calcu-
lating a Bonferroni corrected p-threshold based on all 600 metabolite
variables (p = 8.33  105).
3 | RESULTS
The study group consisted of 318 healthy infants of the Sophia Pluto
cohort with complete body composition data and blood samples. One
hundred forty-three (45%) were girls and 66.4% of the infants was
Caucasian. Clinical characteristics are presented in Table 1. Of all
infants, 38.7% received exclusive breastfeeding (EBF) until the age of
3 months and 25.5% of the infants were exclusive formula fed (EFF).
This did not differ between boys and girls. Body composition parame-
ters were not different between boys and girls, except for visceral fat
at 3 months, which is higher in boys than in girls (p = 0.017). Abdomi-
nal subcutaneous and visceral fat and truncal:peripheral fat ratio (T:P-
ratio) ratio decreased over time from age 3 months to 2 years. Based
on the WHO criteria for weight-for-length SDS, 93.1% of the infants
had normal weight, 5.7% was underweight and 1.3% had overweight
at 2 years of age. None of the infants classified had obesity. This was
not different between boys and girls. Infants were divided in tertiles
based on T:P-ratio (Table 2).
3.1 | Association between metabolite variables at
3 months and body composition at 2 years
There was a modest association between the plasma metabolite
profile at 3 months of age and body composition at 2 years of age,
measured as truncal:peripheral ratio (T:P-ratio) (R2X = 0.224, R2
Y = 0.351, Q2 = 0.185, CV-ANOVA = 5.71х108) (Figure 1). Using
random forest, modest predictions for infants with high and low
T:P-ratio at 2 years were achieved using 3 month plasma metabo-
lite profiles with an predictive performance of 75.8%, a sensitivity
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TABLE 1 Clinical characteristics
All N = 318 Boys N = 175 Girls N = 143 p-value
Gestational age (weeks) 39.74 (1.21) 39.66 (1.28) 39.83 (1.13) 0.224
Sex (%) 55.0 45.0 0.479
Birth weight SDS 0.28 (1.15) 0.42 (1.08) 0.11 (1.20) 0.017
Birth length SDSa 0.68 (1.20) 0.83 (1.19) 0.49 (1.19) 0.058
Ethnicity (%) 0.060
Caucasian 211 (66.4%) 122 (69.7%) 89 (62.2%)
Black 21 (6.6%) 5 (2.9%) 16 (11.2%)
Asian 3 (0.9%) 1 (0.6%) 2 (1.4%)
Latin 1 (0.3%) 1 (0.6%) 0
Other 64 (20.1%) 35 (20.0%) 29 (20.3%)
Missing 18 (5.7%) 11 (6.2%) 7 (4.9%)
Mode of delivery 0.479
Vaginal 219 (68.9%) 115 94
Caesarean Section 98 (30.8%) 59 39
Missing 1 (0.3%) 1 0
3 months N = 318 N = 175 N = 143
Age (months) 2.99 (2.92–3.09) 2.99 (2.92–3.09) 2.99 (2.92–3.06) 0.615
Feeding mode 0.597
Exclusive breastfeeding 123 (38.7%) 64 59
Exclusive formula feeding 81 (25.5%) 48 33
Mix feeding 113 (35.5%) 62 51
Weight-for-length SDS 0.22 (1.01) 0.27 (0.95) 0.15 (1.08) 0.306
Length SDS 0.35 (0.87) 0.49 (0.81) 0.17 (0.92) 0.001
Peripheral skinfolds (mm) 15 (13–16) 15 (13–17) 14 (13–16) 0.139
Truncal skinfolds (mm) 13 (11.5–16) 13 (11–16) 14 (12–17) 0.633
T:P-ratio 0.93 (0.81–1.09) 0.92 (0.81–1.07) 1.00 (0.81–1.11) 0.112
Abdominal subcutaneous fat (cm) 0.41 (0.32–0.49) 0.41 (0.34–0.49) 0.40 (0.32–0.49) 0.787
Visceral fat (cm) 2.36 (0.57) 2.42 (0.58) 2.29 (0.54) 0.048
S:V-ratio 0.17 (0.13–0.22) 0.16(0.13–0.21) 0.18(0.14–0.23) 0.111
2 years N = 318 N = 175 N = 143
Age (months) 24.02 (23.92–24.25) 24.02 (23.92–24.21) 24.08 (23.92–24.35) 0.119
Weight-for-length SDS 0.41 (1.06) 0.41 (1.13) 0.41 (0.97) 0.945
Underweight 18 (5.7%) 10 8 0.720
Normal 296 (93.1%) 162 134
Overweight 4 (1.3%) 3 1
Obese 0 0 0
Length SDS 0.22 (1.01) 0.28 (1.04) 0.15 (0.96) 0.250
Peripheral skinfolds (mm) 16 (14–19) 16 (14–19) 16 (14–18) 0.741
Truncal skinfolds (mm) 13 (11–15) 13 (11–15) 13 (11–15) 0.994
T:P-ratio 0.79 (0.67–0.93) 0.79 (0.68–0.94) 0.78 (0.65–0.92) 0.686
Abdominal subcutaneous fat (cm) 0.32 (0.26–0.40) 0.32 (0.26–0.40) 0.34 (0.26–0.39) 0.787
Visceral fat (cm) 2.12 (1.82–2.51) 2.11 (1.77–2.49) 2.14 (1.84–2.56) 0.387
S:V-ratio 0.16 (0.13–0.22) 0.16 (0.12–0.21) 0.15 (0.12–0.20) 0.280
Note: Data expressed as mean (SD) or median (IQR). Significant p-values are boldfaced.
Abbreviations: BMI, body mass index; S:V-ratio = subcutaneous:visceral fat ratio; SDS, standard deviation score; T:P-ratio, Truncal: peripheral skinfold
ratio.
aBirth weight SDS n = 175.
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of 100% and a specificity of 50.0%. Meaning that 100% of the
infants with a high T:P-ratio at 2 years of age was predicted to
have a high T:P-ratio based on their metabolite profile at 3 months,
while 50.0% of the infants with a low T:P-ratio prediction based on
their plasma metabolite profile did have a low T:P-ratio measured
at 2 years of age.
TABLE 2 Clinical characteristics and
body composition of infants with high,
middle and low trunk: peripheral fat ratio
Low Middle High
T:P-ratio (range) <0.72 0.72–0.88 >0.88
T:P-ratio (mean ± SD) 0.62 ± 0.07 0.79 ± 0.05 1.03 ± 0.12
Sex (F/M) 51/55 39/49 43/60
Feeding type (EBF/EFF/Mix) 39/30/37 36/23/29 39/25/39
3 months
Peripheral skinfolds (mm) 14.48 ± 2.54 14.95 ± 2.78 14.96 ± 2.94
Trunk skinfolds (mm) 12.97 ± 3.04a 14.47 ± 3.15a 14.76 ± 3.87a
Total skinfolds (mm) 27.45 ± 5.21a 29.42 ± 5.70a 29.72 ± 9.93a
Abdominal subcutaneous fat (cm) 0.41 ± 0.11 0.40 ± 0.11 0.43 ± 0.12
Visceral fat (cm) 2.41 ± 0.56 2.35 ± 0.57 2.34 ± 0.57
2 years
Peripheral skinfolds (mm) 18.13 ± 6.25a 16.98 ± 5.23a 14.77 ± 4.77a
Trunk skinfolds (mm) 11.18 ± 6.22a 13.36 ± 6.85a 15.12 ± 6.69a
Total skinfolds (mm) 29.31 ± 5.25 30.34 ± 5.23 29.89 ± 4.77
Abdominal subcutaneous fat (cm) 0.32 ± 0.09 0.33 ± 0.09 0.36 ± 0.10
Visceral fat (cm) 2.24 ± 0.64 2.27 ± 0.57 2.08 ± 0.51a
Abbreviations: EBF, exclusively breastfed; EFF, exclusively formula fed; F, female; M, male; Mix, mixed
fed; SD, standard deviation; T:P-ratio, truncal: peripheral skinfold ratio.
aIndicates a significant (p < 0.05) difference between groups. All p-values were calculated using
generalized linear models applied simultaneously to all three groups.
F IGURE 1 Evaluation of the ability for 3 month metabolite profile to predict truncal:peripheral fat ratio at 2 years. (A) Scores plot of PLS-DA
model calculated on individuals with ‘high’ and ‘low’ truncal:peripheral fat ratio after the dataset had been stratified into three groups of ‘high’,
‘middle’ and ‘low’ truncal:peripheral fat ratio. (B) Receiver operating characteristic curve showing diagnostic ability of the model to identify
individuals with high and low truncal: peripheral fat ratio. (C) Prediction matrix showing rates of correct classification
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Of the 15 most strongly associated metabolite variables with
T:P-ratio at 2 years of age, two passed ‘false discover rate’ (FDR)
correction based on a Bonferroni corrected p-threshold
(p = 8.33  105) and eight passed Benjamini-Hochberg based on
all 600 variables (Table 3). Of these, nine metabolites were anno-
tated: Lysophosphatidylserine 22:2 (LysoPS (22:2)) had a fold
change of 1.48 (p = 2.32  105) in infants with a high T:P-ratio
compared to infants with low T:P-ratio. Meaning that the relative
abundance of LysoPS (22:2) was 48% higher in infants with a
high T:P-ratio at 2 years, compared to infants with low a T:P-ratio
at 2 years of age. For dimethylarginine, esterone glucoronide
(C24H30O8), the C13 isotope of hydroxypentaoxolanostenoic acid
(C30H40O8), hydroxyprogesterone glucoronide (C27H38O9),
lysophosphatidylethanolamine (20:1) (LysoPE(20:1)) the fold
changes were 1.85 (p = 0.0002), 1.65 (p = 0.0003), 1.31
(p = 0.0003), 1.31 (p = 0.0007) and 1.09 (p = 0.0005), resp.
Other annotated metabolites were lysophosphatidylglycerol
(16:0) (LysoPG(16:0)), C30H40O8 and lysophosphosphatidic acid
(22:1) (LysoPA (22:1)). All had a fold change above 1.
Having identified candidate biomarkers at age 3 months for the T:
P-ratio at 2 years of age, we wanted to determine the inter-relation
between the biomarkers, body composition and potentially con-
founding factors. After correcting for sex, birth weight and feeding
type (Table 3) all biomarkers remained significant (p < 0.05) with two
passing a Bonferroni corrected p-threshold and six passing Benjamini–
Hochberg correction. Additional corrections for BMI SDS at age
3 months, weight-for-length SDS and total skinfolds at age 2 years
did not change the results (data not shown). Of the 15 metabolite var-
iables, four were already associated with T:P ratio at 3 months of age
(p < 0.05) (Table S1).
Eleven of the 15 metabolite variables, identified at age 3 months,
were significantly associated with visceral fat at 2 years of age
(p < 0.05), though none passed FDR based on either Bonferroni or
Benjamini-Hochberg (Table 4). All had a fold change below 1, meaning
that the relative abundance of these metabolite variables was lower
at 3 months in infants with higher visceral fat at 2 years. T:P-ratio and
visceral fat were not correlated, R = 0.073 (p = 0.220). We also
found that some of the 15 metabolite variables were associated with
peripheral and trunk fat levels although none of these associations
passed FDR (data not shown).
3.2 | Difference between boys and girls
We found differences in the association between the 15 metabolite
variables and the T:P-ratio between boys and girls (Figure S1). In boys,
TABLE 3 Panel of 15 plasma metabolite variables at 3 months most strongly associated with truncal: peripheral fat ratio at 2 years













LysoPS(22:2) 578.3481 0.49 5.99  1006a,b 2.16  1005a,b 1.48 4.95  1005 1.58 0.021 1.37
Unkown 1015.6761 0.39a,b 2.28  1005a,b 3.79  1005a,b 1.57 0.0002 1.64 0.033 1.49
Dimethylarginine 203.0533 0.33 0.0001b 0.0002b 1.85 0.0001 2.20 0.074 1.50
C24H30O8 447.2815 0.47 0.0002
b 0.0003b 1.65 0.0009 1.80 0.032 1.49
C13 isotope of
C30H40O8
530.3357 0.52 0.0003b 0.0003b 1.31 0.0069 1.26 0.016 1.36
C27H38O9 507.3104 0.50 0.0004
b 0.0007b 1.31 0.0015 1.36 0.072 1.26
Unknown 431.2617 0.39 0.0005b 0.0007b 1.38 0.0003 1.50 0.104 1.26
LysoPE(20:1) 508.3468 0.66 0.0008b 0.0005b 1.09 0.0053 1.08 0.059 1.09
Unknown 590.3393 0.47 0.0018 0.0017 1.48 0.0063 1.49 0.052 1.47
LysoPG(16:0) 486.2760 0.54 0.0022 0.0026 1.14 0.0240 1.11 0.054 1.17
C30H40O8 529.3246 0.47 0.0034 0.0034 1.60 0.0075 1.73 0.114 1.46
LysoPA(22:1) 495.3132 0.86 0.0040 0.0051 1.41 0.0122 1.42 0.101 1.39
Unknown 200.8896 0.319 0.0043 0.0031 0.91 0.0066 0.91 0.069 0.90
Unknown 162.9649 0.367 0.0046 0.0075 2.03 0.0021 2.76 0.418 1.29
Unknown 222.8750 0.38 0.0050 0.0022 0.87 0.1124 0.95 0.006 0.79
Note: ‘p-value’ are the unadjusted p-values. ‘Corrected p-values’ have been adjusted for sex, birth weight and feeding type. All p-values were calculated
using generalized linear models comparing high and low tertiles of trunk: peripheral ratio. Fold change is calculated relative to the ‘low’ group. Putative
annotations: C24H30O8 – Esterone Glucoronide, C27H38O9 –Hydroxyprogesterone Glucoronide, C30H40O8 – Hydroxypentaoxolanostenoic acid.
Abbreviations: LysoPA, lysophosphosphatidic acid; LysoPE, lysophosphatidylethanolamine; LysoPG, lysophosphatidylglycerol; LysoPS,
lysophosphatidylserine; m/z, mass-to-charge ratio.
aPassing FDR based on Bonferoni.
bPassing FDR based on Benjamini-Hochberg.
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TABLE 4 Panel of 15 plasma metabolite variables at 3 months associated with visceral fat at 2 years
All Individuals Boys Girls
p-value Corrected p-value Fold change p-value Fold change p-value Fold change
LysoPS (22:2) 0.003 0.004 0.75 0.084 0.80 0.010 0.68
Unkown 0.007 0.008 0.72 0.109 0.78 0.026 0.64
Dimethylarginine 0.002 0.003 0.62 0.032 0.62 0.025 0.61
C24H30O8 0.009 0.010 0.71 0.105 0.74 0.028 0.66
C13 isotope of C30H40O8 0.005 0.008 0.79 0.108 0.83 0.015 0.73
C27H38O9 0.014 0.016 0.81 0.191 0.86 0.025 0.74
Unknown 0.209 0.207 0.88 0.209 0.85 0.523 0.91
LysoPE (20:1) 0.081 0.096 0.95 0.124 0.95 0.299 0.95
Unknown 0.023 0.028 0.74 0.142 0.77 0.071 0.69
LysoPG (16:0) 0.046 0.036 0.89 0.332 0.93 0.077 0.83
C30H40O8 0.002 0.002 0.60 0.046 0.64 0.010 0.55
LysoPA(22:1) 0.042 0.051 0.77 0.236 0.82 0.079 0.71
Unknown 0.435 0.459 1.03 0.518 1.02 0.595 1.04
Unknown 0.001 0.003 0.49 0.007 0.44 0.090 0.55
Unknown 0.715 0.627 0.98 0.203 0.93 0.511 1.06
Note: ‘p-value’ are the unadjusted p-values. ‘Corrected p-values’ have been adjusted for sex, birthweight and feeding type. All p-values were calculated
using generalized linear models comparing high and low tertiles of visceral fat at 2 years of age. Fold change is calculated relative to the ‘low’ group.
Putative annotations: C24H30O8 – Esterone Glucoronide, C27H38O9 –Hydroxyprogesterone Glucoronide, C30H40O8 – Hydroxypentaoxolanostenoic acid.
Abbreviations: LysoPA, lysophosphosphatidic acid; LysoPE, lysophosphatidylethanolamine; LysoPG, lysophosphatidylglycerol; LysoPS,
lysophosphatidylserine.
TABLE 5 Relative abundance of 15 plasma metabolite variables in different feeding types
Relative Abundance Difference
Breast Mixed Formula p-value
LysoPS(22:2) 1.57 1.57 1.68 0.505
Unknown 0.88 0.94 0.99 0.357
Dimethylarginine 3.92 3.98 4.59 0.338
C24H30O8 6.83 7.31 8.19 0.202
C13 isotope of C30H40O8 8.30 7.52 7.62 0.351
C27H38O9 35.97 38.51 38.76 0.442
Unknown 2.83 2.91 3.30 0.159
LysoPE(20:1) 48.04 44.90 43.70 0.002
Unknown 27.92 27.69 31.88 0.345
LysoPG(16:0) 6.10 7.23 7.40 0.001
C30H40O8 13.20 12.92 14.14 0.684
LysoPA(22:1) 8.84 8.67 9.77 0.452
Unknown 1.88 1.91 1.92 0.568
Unknown 4.09 3.92 3.77 0.702
Unknown 1.07 1.18 1.15 0.193
Note: All p-values were calculated using generalized liner models comparing relative abundance in exclusive breast fed, mixed and exclusive formula fed
infants. Significant p-values are boldfaced. Relative abundance is shown in arbitrary units. Putative annotations: C24H30O8 – Esterone Glucoronide, C27H38
O9 –Hydroxyprogesterone Glucoronide, C30H40O8 – Hydroxypentaoxolanostenoic acid.
Abbreviations: LysoPA, lysophosphosphatidic acid; LysoPE, lysophosphatidylethanolamine; LysoPG, lysophosphatidylglycerol; LysoPS,
lysophosphatidylserine.
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the model had a predictive performance of 32.2% between individuals
in the highest and lowest tertile of T:P-ratio at 2 years (R2X = 0.204,
R2Y = 0.595, Q2 = 0.322, CV-ANOVA = 3.05  108). In girls, the
predictive performance of the model was 11.7% (R2X = 0.197, R2
Y = 0.539, Q2 = 0.117, CV-ANOVA = 0.038). In boys, all metabolic
variables except for one unknown metabolite variable showed a sig-
nificant (p < 0.05) association with T:P-ratio at 2 years. Of these
14 metabolic variables, 13 had a fold change greater than 1, which
means that the relative abundance of the metabolic variables
were higher in boys with high T:P-ratio compared to boys with low
T:P-ratio. In girls, 5 out of 15 metabolic variables were significantly
associated with T:P-ratio (Table 3). Four of these had a fold change
greater than 1. An unknown metabolite variable had an fold change of
0.79 (p = 0.006) in girls, meaning that this metabolite variable had a
lower relative abundance in girls with a high T:P-ratio, compared to
girls with a low T:P-ratio. It was the only metabolic variable that was
stronger associated with T:P-ratio in girls compared to boys.
3.3 | Effect of feeding type
T:P-ratio at 2 years of age was not different between infants with exclu-
sive breastfeeding (EBF), exclusive formula feeding (EFF) and mixed feed-
ing. Of the 15 metabolite variables, lysophosphatidylethanolamine (20:1)
(LysoPE(20:1)) and the isotope of Lysophosphoglycerol (16:0) (LysoPG
(16:0)) were significantly associated with feeding type (Table 5). LysoPE
(20:1) had a higher relative abundance in EBF infants and LysoPG(16:0)
had an higher relative abundance in EFF infants.
4 | DISCUSSION
Our data show that the plasma metabolite profile at 3 months of age can
modestly predict body composition at 2 years of age, based on truncal:
peripheral fat ratio (T:P-ratio), with a predictive value of 75.8%, sensitivity
of 100% and a specificity of 50%. The predictive value was better in boys
than in girls. Of the 15 metabolite variables at 3 months of age that were
most strongly associated with the T:P-ratio at 2 years, 11 were also asso-
ciated with visceral fat at 2 years of age.
We are the first to describe potential biomarkers at 3 months of
age which are associated with body composition outcome at 2 years
of age. It has been reported that metabolic biomarkers are different in
lean children and children with obesity, with especially branched chain
amino acids (BCAAs) concentrations being higher in individuals with
obesity.28 Second, metabolic biomarkers have been reported to be
potentially predictive for unfavourable metabolic outcome in adults,
adolescents and school children with overweight and obesity.29,30
However, it has never been described before that plasma metabolite
profile at 3 months of age are associated with future visceral fat and
proxy of body composition, such as skinfold measurements,4,31 in a
large cohort of healthy infants.
Our results support the hypothesis of a critical window of adipos-
ity programming in early life.3,4 It has been reported that growth and
body composition, especially in the first 6 months of life, are impor-
tant for the development of body composition later in life and for the
adult metabolic profile.3,9 We now add that the plasma metabolic pro-
file in early life is potentially involved in the adiposity programming
and contributes to adiposity at 2 years of age. Our results show
that only four of the associated plasma metabolites associated with
T:P-ratio at 2 years were also associated with T:P-ratio at 3 months of
life. This means the plasma metabolites we found are independent of
the biological progress of body composition.
Of the 15 most strongly associated metabolite variables, 11 were
also significantly associated with abdominal visceral fat at 2 years of
age, with a fold change below 1. Meaning, infants with high visceral
fat at 2 years of age, had lower relative abundance of these metabo-
lite variables at 3 months of age. This is remarkable, since we found
the metabolite variables to be associated with T:P-ratio with a fold
change above 1. We found visceral fat and T:P-ratio not to be corre-
lated at 2 years of age. It has been described that skinfold measure-
ments are correlated with total body fat.31 However, this is mostly
based on the amount of subcutaneous fat instead of visceral fat.32
This could possibly explain, why we found opposite association
between T:P-ratio and visceral fat. Second, it has been described that
especially excessive visceral fat is associated with an unfavourable
metabolic outcome, with more insulin resistance and a higher risk of
diabetes mellitus type II.12,33 Since we found an association between
metabolite variables at 3 months of age with visceral fat at 2 years,
our findings could suggest that metabolite profile in early life is also
important for programming the metabolic outcome later in life.
Our results showed that plasma dimethylarginine and
lysophosphatidylserine 22:2 (LysoPS 22:2) at 3 months of age are
highly correlated with body composition outcomes at 2 years. In
adults, higher dimethylarginine levels have been associated with dys-
lipidemia and accelerated atherosclerosis and found to be predictive
for cardiovascular events.34,35 One research group described
dimethylarginine levels to be higher in teenagers obesity compared to
their lean peers.36 LysoPS 22:2 has been mainly studied in rodent and
in vitro studies. These studies show that LysoPS is involved in glucose
uptake in muscle and adipose tissue.37,38 In contrast, it has been
reported that LysoPS levels are lower in hepatic tissue from adults
with obesity, compared to lean peers.39 Since we found LysoPS to be
associated with visceral fat at 2 years of age with a fold change below
1, the mechanism for LysoPS involved with intra-abdominal fat could
possibly differ from subcutaneous fat. We also found plasma
lysophosphatidic acid(22:1) (LysoPA (22:1)) at 3 months of age to be
associated with body composition outcome at 2 years. LysoPA has
been described to interact with mTOR signalling, affecting body com-
position due to changes in lean body mass.40
Dimethylarginine, LysoPS and LysoPA have been associated with
inflammatory processes.41–43 It was reported that LysoPS is an emerg-
ing class of signalling compounds44 and could be interacting with Toll-
like receptor dimers (TLR2/6).45 LysoPA has been reported to activate
peroxisome proliferator-activated receptor gamma (PPAR-γ).46 Both
Toll-like receptors and PPAR-γ are known to be involved in the devel-
opment of inflammation, obesity and metabolic syndrome.47,48
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Second, LysoPS, LysoPA, lysophosphatidylethanolamine (LysoPE) and
lysophosphatidylglycerol (LysoPG) are all deacylated products of
phospholipids and are the result of phospholipase A activity.46 Phos-
pholipase A2 is important in lipid metabolism and it has been
described that serum levels of phospholipase A2 are increased in
patients with obesity and inflammation, due to activation of pro-
inflammatory pathways in preadipocytes.49,50 Our findings could,
therefore, suggest that the identified metabolites are involved in adi-
posity development and systematic low grade inflammatory processes
from early age onwards.
Plasma metabolite variables at 3 months of age had a higher pre-
dictive value in boys than in girls. We found no differences between
girls and boys in skinfold measurements and abdominal fat distribu-
tion at 2 years of age. However, it has been described that girls have
a higher fat mass percentage and lower lean body mass, measured
with air displacement plethysmography compared to boys.7 One
research group also found differences in metabolic biomarkers associ-
ated with insulin resistance between female and male adolescents
with obesity.51 Our findings of metabolite differences already present
at a very young age suggest that these metabolite variables may have
different mechanism of action in the adiposity programming of boys
and girls.
Two of the 15 metabolite variables showed a different relative
abundance in infants with different feeding types. This is in line with
our previous findings in other cohorts, where we identified differ-
ences in lipid profile between infants receiving exclusive
breastfeeding compared to infants receiving formula feeding.18,20,52
Since only 2 of the 15 metabolite variables were different across dif-
ferent infant feeding types, the associations we found between
metabolite variables at 3 months of age and body composition out-
come at 2 years of age seemed independent of infant feeding type.
This is the first study reporting plasma metabolite profile at 3 months
that are associated with body composition outcome at 2 years. The
strengths of our study are the longitudinal body composition measure-
ments and collected blood samples in a large group of healthy infants
combined with a validated technique to obtain a detailed metabolic pro-
file. We acknowledge some limitations. Although we did not annotated all
identified metabolite variables, with the level of detail we provide, others
can replicate our work and future annotation is possible. We identified
metabolic variables in a single cohort containing a very low number of
infants developing overweight and no infants developed obesity at the
2 years of age. It was, therefore, not possible to predict obesity based on
metabolic profile. The metabolite variables we found, were associated
with childhood body composition trajectories. They will, therefore, have
to be validated in infants who develop overweight or obesity and in an
independent external cohort to validate generalizability in healthy infants.
In conclusion, we found that the plasma metabolite profile at
3 months of age can modestly predict body composition at 2 years of
age, measured as T:P-ratio. The predictive value was higher in boys
than in girls. Of the 15 highest correlated plasma metabolite variables,
11 were also associated with visceral fat at 2 years. These findings
contribute to our insight into the adiposity programming in the first
months of life.
ACKNOWLEDGMENTS
Sophia Pluto: We thank all infants and their parents for participating in
the Sophia Pluto Study. Furthermore, we greatly acknowledge
Mrs. J. van Nieuwkasteele, Mrs. M. Huibregtse-Schouten, Mrs.
C. Bruinings-Vroombout, Mrs. E. Lems, Ms. N. Khieroe,
Mrs. S. Besteman-Voortman and Mrs. J. Bontenbal-van de Wege,
research nurses, for their assistance with data collection. Cambridge:
We want to thank Dr Benjamin Jenkins for his support in the labora-
tory. After the submission of the original manuscript, Prof David
Dunger sadly passed away. We are hugely indebted to his contribu-
tion to this work, the field in general and his ideas and guidance have
been crucial in getting this work together.
CONFLICT OF INTEREST
BJMvdH is an employee of Danone Nutricia Research.
AUTHOR CONTRIBUTIONS
Albert Koulman, Anita Hokken-Koelega, Susanne Brix, Ken Ong and
David Dunger were in charge of designing the study. Inge van
Beijsterveldt, Kirsten de Fluiter and Anita Hokken-Koelega were in charge
of the cohort, design and collecting of the data and samples. Stuart Snow-
den and Albert Koulman performed the metabolomics and bioinformatic
analysis. Drafting the manuscript was primarily done by Inge van
Beijsterveldt and Stuart Snowden under supervision of Anita Hokken-
Koelega and Albert Koulman. All authors were involved in writing the
manuscript and had final approval of the submitted version.
ORCID
Inge A.L.P. van Beijsterveldt https://orcid.org/0000-0002-0204-
7430
Kirsten S. de Fluiter https://orcid.org/0000-0002-5848-7929
Albert Koulman https://orcid.org/0000-0001-9998-051X
REFERENCES
1. WHO. Report of the Commission on Ending Childhood Obesity. World
Health Organization; 2016 9241510064.
2. Weihrauch-Blüher S, Schwarz P, Klusmann JH. Childhood obesity:
increased risk for cardiometabolic disease and cancer in adulthood.
Metabolism. 2019;92:147-152.
3. Leunissen RW, Kerkhof GF, Stijnen T, Hokken-Koelega A. Timing and
tempo of first-year rapid growth in relation to cardiovascular and
metabolic risk profile in early adulthood. JAMA. 2009;301(21):2234-
2242.
4. Breij LM, Steegers-Theunissen RP, Briceno D, Hokken-Koelega AC.
Maternal and fetal determinants of neonatal body composition. Horm
Res Paediatr. 2015;84(6):388-395.
5. Singh AS, Mulder C, Twisk JW, van Mechelen W, Chinapaw MJ.
Tracking of childhood overweight into adulthood: a systematic review
of the literature. Obes Rev. 2008;9(5):474-488.
6. Geserick M, Vogel M, Gausche R, et al. Acceleration of BMI in early
childhood and risk of sustained obesity. N Engl J Med. 2018;379(14):
1303-1312.
7. Breij LM, Kerkhof GF, De Lucia RE, et al. Longitudinal fat mass and
visceral fat during the first 6 months after birth in healthy infants:
support for a critical window for adiposity in early life. Pediatr Obes.
2017;12(4):286-294.
10 of 12 van BEIJSTERVELDT ET AL.
8. Freedman DS, Wang J, Maynard LM, et al. Relation of BMI to fat and
fat-free mass among children and adolescents. Int J Obes. 2005;29(1):
1-8.
9. de Fluiter KS, van Beijsterveldt I, Breij LM, Acton D, Hokken-
Koelega ACS. Association between fat mass in early life and later fat
mass trajectories. JAMA Pediatr. 2020;174(12):1141-1148.
10. Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking
obesity to its source. Cell. 2007;131(2):242-256.
11. Botton J, Heude B, Kettaneh A, et al. Cardiovascular risk factor levels
and their relationships with overweight and fat distribution in chil-
dren: the Fleurbaix Laventie Ville Sante II study. Metabolism. 2007;
56(5):614-622.
12. Hamdy O, Porramatikul S, Al-Ozairi E. Metabolic obesity: the paradox
between visceral and subcutaneous fat. Curr Diabetes Rev. 2006;2(4):
367-373.
13. Breij LM, Abrahamse-Berkeveld M, Acton D, De Lucia RE, Ong KK,
Hokken-Koelega ACS. Impact of early infant growth, duration of
breastfeeding and maternal factors on Total body fat mass and vis-
ceral fat at 3 and 6 months of age. Ann Nutr Metab. 2017;71(3–4):
203-210.
14. Breij LM, Mulder MT, van Vark-van der Zee LC, Hokken-
Koelega ACS. Appetite-regulating hormones in early life and relation-
ships with type of feeding and body composition in healthy term
infants. Eur J Nutr. 2017;56(4):1725-1732.
15. Oliosa PR, Zaniqueli DDA, Barbosa MCR, Mill JG. Relationship
between body composition and dyslipidemia in children and
adolescentes. Cien Saude Colet. 2019;24(10):3743-3752.
16. Lozano P, Henrikson NB, Morrison CC, et al. Lipid screening in child-
hood and adolescence for detection of multifactorial dyslipidemia:
evidence report and systematic review for the US preventive services
task force. JAMA. 2016;316(6):634-644.
17. Koulman A, Prentice P, Wong MCY, et al. The development and vali-
dation of a fast and robust dried blood spot based lipid profiling
method to study infant metabolism. Metabolomics. 2014;10(5):1018-
1025.
18. Prentice P, Koulman A, Matthews L, Acerini CL, Ong KK, Dunger DB.
Lipidomic analyses, breast- and formula-feeding, and growth in
infants. J Pediatr. 2015;166(2):276-281.
19. Acharjee A, Prentice P, Acerini C, et al. The translation of lipid profiles
to nutritional biomarkers in the study of infant metabolism. Met-
abolomics. 2017;13(3):25.
20. Furse S, Billing G, Snowden SG, Smith J, Goldberg G, Koulman A.
Relationship between the lipid composition of maternal plasma and
infant plasma through breast milk. Metabolomics. 2019;15(10):129.
21. Ay L, Hokken-Koelega AC, Mook-Kanamori DO, et al. Tracking and
determinants of subcutaneous fat mass in early childhood: the gener-
ation R study. Int J Obes. 2008;32(7):1050-1059.
22. Talma H, Schonbeck Y, Bakker B, Hirasing RA, Buuren S.
Groeidiagrammen 2010: Handleiding bij het meten en wegen van kin-
deren en het invullen van groeidiagrammen. TNO; 2010.
23. De Lucia RE, Modi N, Uthaya S, et al. Ultrasound estimates of visceral
and subcutaneous-abdominal adipose tissues in infancy. J Obes.
2013;2013:951954–951959.
24. Jenkins B, Ronis M, Koulman A. LC–MS Lipidomics: Exploiting a Sim-
ple High-Throughput Method for the Comprehensive Extraction of
Lipids in a Ruminant Fat Dose-Response Study. Metabolites. 2020;10
(7):296-324. https://doi.org/10.3390/metabo10070296
25. Chambers MC, Maclean B, Burke R, et al. A cross-platform toolkit for
mass spectrometry and proteomics. Nat Biotechnol. 2012;30(10):
918-920.
26. Kuhl C, Tautenhahn R, Bottcher C, Larson TR, Neumann S. CAMERA:
an integrated strategy for compound spectra extraction and annota-
tion of liquid chromatography/mass spectrometry data sets. Anal
Chem. 2012;84(1):283-289.
27. WHO. Nutrition Landscape Information System (NLIS) country profile
indicators: interpretation guide. 2019.
28. Butte NF, Liu Y, Zakeri IF, et al. Global metabolomic profiling
targeting childhood obesity in the Hispanic population. Am J Clin Nutr.
2015;102(2):256-267.
29. Zhao X, Gang X, Liu Y, Sun C, Han Q, Wang G. Using Metabolomic
profiles as biomarkers for insulin resistance in childhood obesity: a
systematic review. J Diabetes Res. 2016;2016:8160545.
30. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-
related metabolic signature that differentiates obese and lean
humans and contributes to insulin resistance. Cell Metab. 2009;
9(4):311-326.
31. Wohlfahrt-Veje C, Tinggaard J, Winther K, et al. Body fat throughout
childhood in 2647 healthy Danish children: agreement of BMI, waist
circumference, skinfolds with dual X-ray absorptiometry. Eur J Clin
Nutr. 2014;68(6):664-670.
32. Horan M, Gibney E, Molloy E, McAuliffe F. Methodologies to assess
paediatric adiposity. Ir J Med Sci. 2015;184(1):53-68.
33. Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, athero-
sclerosis, and cardiometabolic disease: a position statement. Lancet
Diabetes Endocrinol. 2019;7(9):715-725.
34. Davids M, Teerlink T. Asymmetric dimethylarginine (ADMA) and car-
diovascular disease. Ned Tijdschr Klin Chem Labgeneesk. 2012;37(1):
10-14.
35. Landim MB, Casella Filho A, Chagas AC. Asymmetric dimethylarginine
(ADMA) and endothelial dysfunction: implications for atherogenesis.
Clinics (Sao Paulo). 2009;64(5):471-478.
36. Gruber HJ, Mayer C, Meinitzer A, et al. Asymmetric dimethylarginine
(ADMA) is tightly correlated with growth in juveniles without correla-
tions to obesity related disorders. Exp Clin Endocrinol Diabetes. 2008;
116(9):520-524.
37. Yea K, Kim J, Lim S, et al. Lysophosphatidylserine regulates blood glu-
cose by enhancing glucose transport in myotubes and adipocytes.
Biochem Biophys Res Commun. 2009;378(4):783-788.
38. Chang HW, Inoue K, Bruni A, Boarato E, Toffano G. Stereoselective
effects of lysophosphatidylserine in rodents. Br J Pharmacol. 1988;
93(3):647-653.
39. Ruby MA, Massart J, Hunerdosse DM, et al. Human carboxylesterase
2 reverses obesity-induced diacylglycerol accumulation and glucose
intolerance. Cell Rep. 2017;18(3):636-646.
40. Joy JM, Gundermann DM, Lowery RP, et al. Phosphatidic acid
enhances mTOR signaling and resistance exercise induced hypertro-
phy. Nutr Metab (Lond). 2014;11:29.
41. Nijveldt RJ, Teerlink T, Van Der Hoven B, et al. Hoge plas-
maconcentratie van asymmetrisch dimethylarginine (ADMA) als
onafhankelijke sterftevoorspeller bij intensivecarepatiënten. Ned
Tijdschr Geneeskd. 2004;148(16):782-787.
42. Frasch SC, Bratton DL. Emerging roles for lysophosphatidylserine in
resolution of inflammation. Prog Lipid Res. 2012;51(3):199-207.
43. Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid
production. Biochim Biophys Acta. 2008;1781(9):513-518.
44. Shanbhag K, Mhetre A, Khandelwal N, Kamat SS. The
lysophosphatidylserines-an emerging class of signalling lysophospho
lipids. J Membr Biol. 2020;253(5):381-397.
45. Bexkens ML, Houweling M, Burgers PC, Luider TM, Tielens AGM,
van Hellemond JJ. A mono-acyl phospholipid (20:1 lyso-PS) activates
toll-like receptor 2/6 hetero-dimer. Chem Phys Lipids. 2020;232:
104951.
46. Luquain C, Sciorra VA, Morris AJ. Lysophosphatidic acid signaling:
how a small lipid does big things. Trends Biochem Sci. 2003;28(7):
377-383.
47. Jialal I, Kaur H, Devaraj S. Toll-like receptor status in obesity and met-
abolic syndrome: a translational perspective. J Clin Endocrinol Metab.
2014;99(1):39-48.
van BEIJSTERVELDT ET AL. 11 of 12
48. Shao X, Wang M, Wei X, et al. Peroxisome proliferator-activated
receptor-γ: master regulator of adipogenesis and obesity. Curr Stem
Cell Res Ther. 2016;11(3):282-289.
49. Leiguez E, Motta P, Maia Marques R, Lomonte B, Sampaio SV,
Teixeira C. A Representative GIIA Phospholipase A2 Activates Pre-
adipocytes to Produce Inflammatory Mediators Implicated in Obesity
Development. Biomolecules. 2020;10(12):1593-1612. https://doi.org/
10.3390/biom10121593
50. Garces F, Lopez F, Niño C, et al. High plasma phospholipase A2 activ-
ity, inflammation markers, and LDL alterations in obesity with or with-
out type 2 diabetes. Obesity (Silver Spring). 2010;18(10):2023-2029.
51. Newbern D, Gumus Balikcioglu P, Balikcioglu M, et al. Sex differences
in biomarkers associated with insulin resistance in obese adolescents:
metabolomic profiling and principal components analysis. J Clin
Endocrinol Metab. 2014;99(12):4730-4739.
52. Furse S, Richardson L, Koulman A. The validation of biomarkers of
metabolic efficacy in infant nutrition. Nutr Bull. 2018;43(3):296-300.
SUPPORTING INFORMATION
Additional supporting information may be found in the online version
of the article at the publisher's website.
How to cite this article: van Beijsterveldt IALP, Snowden SG,
Myers PN, et al. Metabolomics in early life and the association
with body composition at age 2 years. Pediatric Obesity. 2021;
e12859. doi:10.1111/ijpo.12859
12 of 12 van BEIJSTERVELDT ET AL.
